Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514)
- 1 January 1999
- book chapter
- Published by Springer Nature
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- 768: Phase II study of a multi-targeted antifolate (LY231514) (MTA) as first line therapy in patients with locally advanced or metastatic colorectal cancer (MCC)European Journal Of Cancer, 1997
- 34 Phase II study of LY231514 in patients with advanced non-small cell lung cancer (NSCLC)Lung Cancer, 1997
- Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasisCancer Chemotherapy and Pharmacology, 1997
- 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool expansion in cultured L1210 cells treated with inhibitors of thymidylate synthaseBiochemical Pharmacology, 1995
- A dideazatetrahydrofolate analog lacking a chiral center at C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthaseJournal of Medicinal Chemistry, 1992
- Phase II trials of trimetrexate in advanced adult soft tissue sarcomaAnnals of Oncology, 1991
- Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modificationsJournal of Medicinal Chemistry, 1991
- Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferaseBiochemistry, 1991
- Polyglutamation of methotrexate. Is methotrexate a prodrug?Journal of Clinical Investigation, 1985
- Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterinJournal of Medicinal Chemistry, 1985